Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Summary as of May 17, 2018

May 17, 2018 - By Steve Marquez

During 2017 Q4 the big money sentiment decreased to 1.2. That’s change of 0.53, from 2017Q3’s 1.73. 23 investors sold all, 48 reduced holdings as Aerie Pharmaceuticals, Inc. ratio dived. 64 increased positions while 21 funds acquired positions. Funds hold 34.86 million shares thus 1.29% more from 2017Q3’s 34.42 million shares.
Goldman Sachs holds 0% or 157,977 shs. Axa reported 172,648 shs. 1,098 are held by Perigon Wealth Mgmt Ltd Liability. Federated Investors Pa invested in 9,537 shs or 0% of the stock. Castleark Limited Liability Company holds 45,223 shs. 4,472 are held by Amalgamated Bancorp. Bailard invested in 22,650 shs or 0.09% of the stock. State Of Wisconsin Inv Board invested in 0.01% or 32,400 shs. Creative Planning holds 3,600 shs. Savings Bank Of Nova Scotia stated it has 22,200 shs or 0.01% of all its holdings. Royal Retail Bank Of Canada reported 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). The Iowa-based Principal Fincl Incorporated has invested 0% in Aerie Pharmaceuticals, Inc. (NASDAQ:AERI). Consulate owns 10,500 shs. Walleye Trading Limited Com invested in 56 shs. Phoenix Invest Adviser Lc holds 300 shs or 0.02% of its capital.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Ratings Coverage

In total 6 analysts cover Aerie Pharma (NASDAQ:AERI). “Buy” rating has 6, “Sell” are 0, while 0 are “Hold”. (NASDAQ:AERI) has 100% bullish analysts. 11 are the (NASDAQ:AERI)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Monday, December 18 Cantor Fitzgerald maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Tuesday, May 8 the company was maintained by Cantor Fitzgerald. On Wednesday, May 9 the firm has “Buy” rating by H.C. Wainwright given. The stock rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, February 28. In Thursday, March 1 report H.C. Wainwright maintained the stock with “Buy” rating. On Tuesday, January 2 Stifel Nicolaus maintained Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) with “Buy” rating. On Thursday, March 29 the stock of Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) has “Buy” rating given by Mizuho. In Wednesday, January 24 report Canaccord Genuity maintained it with “Buy” rating and $86.0 target. On Wednesday, May 9 the firm has “Buy” rating given by Mizuho. In Friday, February 16 report H.C. Wainwright reinitiated it with “Buy” rating and $78 target. Listed here are Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) PTs and latest ratings.

09/05/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0000 Maintain
09/05/2018 Broker: Mizuho Rating: Buy New Target: $77.0000 Maintain
08/05/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0000 Maintain
29/03/2018 Broker: Mizuho Rating: Buy New Target: $87.0000 Maintain
01/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $78.0 Maintain
28/02/2018 Broker: Cantor Fitzgerald Rating: Buy New Target: $86.0 Maintain
16/02/2018 Broker: H.C. Wainwright Old Rating: Buy New Rating: Buy New Target: $78 Reinitiate
26/01/2018 Broker: Seaport Global Rating: Buy New Target: $78 Initiates Coverage On
24/01/2018 Broker: Canaccord Genuity Rating: Buy New Target: $86.0 Maintain
02/01/2018 Broker: Stifel Nicolaus Rating: Buy New Target: $80.0 Maintain

The stock decreased 0.10% or $0.05 during the last trading session, hitting $51.15.Currently Aerie Pharmaceuticals, Inc. is uptrending after 16.25% change in last May 17, 2017. AERI has also 226,563 shares volume. AERI outperformed the S&P 500 by 4.70%.

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases.The company has $2.02 billion market cap. The Company’s lead product candidate includes Rhopressa, a once-daily eye drop for the reduction of intraocular pressure in patients with glaucoma or ocular hypertension.Last it reported negative earnings. The firm is also developing Roclatan, a once-daily eye drop to reduce IOP that is in Phase III registration trials to treat patients with open-angle glaucoma and ocular hypertension.

For more Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) news posted briefly go to: Businesswire.com, Globenewswire.com, Benzinga.com, Benzinga.com or Gurufocus.com. The titles are as follows: “Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8 …” posted on April 26, 2018, “Investor Expectations to Drive Momentum within Roper Technologies, Inter Parfums, SunCoke Energy Partners, Aerie …” on May 03, 2018, “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure” with a publish date: May 08, 2018, “Benzinga Pro’s 5 Stocks To Watch Today” and the last “9 Stocks Ron Baron Continues to Buy” with publication date: May 17, 2018.

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.